Clearstead Advisors LLC Purchases 5,458 Shares of Medtronic PLC $MDT

Clearstead Advisors LLC boosted its position in shares of Medtronic PLC (NYSE:MDT) by 14.1% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 44,117 shares of the medical technology company’s stock after buying an additional 5,458 shares during the quarter. Clearstead Advisors LLC’s holdings in Medtronic were worth $4,202,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Medtronic by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 126,909,406 shares of the medical technology company’s stock valued at $11,062,693,000 after purchasing an additional 1,895,165 shares during the period. Geode Capital Management LLC increased its position in Medtronic by 1.1% during the second quarter. Geode Capital Management LLC now owns 28,227,006 shares of the medical technology company’s stock worth $2,448,699,000 after buying an additional 310,684 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Medtronic by 0.9% in the third quarter. Bank of New York Mellon Corp now owns 21,468,260 shares of the medical technology company’s stock valued at $2,044,637,000 after buying an additional 192,410 shares during the period. Massachusetts Financial Services Co. MA lifted its position in shares of Medtronic by 0.5% in the third quarter. Massachusetts Financial Services Co. MA now owns 21,086,499 shares of the medical technology company’s stock valued at $2,008,278,000 after buying an additional 98,220 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in shares of Medtronic by 3.9% during the 2nd quarter. Invesco Ltd. now owns 17,647,149 shares of the medical technology company’s stock worth $1,538,302,000 after acquiring an additional 666,557 shares during the period. Institutional investors own 82.06% of the company’s stock.

Medtronic Price Performance

Shares of NYSE MDT opened at $98.54 on Tuesday. Medtronic PLC has a fifty-two week low of $79.55 and a fifty-two week high of $106.33. The business has a fifty day moving average price of $99.03 and a two-hundred day moving average price of $96.80. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. The stock has a market capitalization of $126.33 billion, a PE ratio of 27.45, a P/E/G ratio of 2.43 and a beta of 0.71.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.88%. The firm had revenue of $9.02 billion for the quarter, compared to the consensus estimate of $8.89 billion. During the same period in the prior year, the company posted $1.38 earnings per share. The business’s revenue for the quarter was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 2.9%. The ex-dividend date was Friday, December 26th. Medtronic’s dividend payout ratio is currently 79.11%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on MDT shares. Daiwa Securities Group increased their price target on Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a research note on Tuesday, November 25th. Leerink Partners decreased their price objective on shares of Medtronic from $120.00 to $119.00 and set an “outperform” rating on the stock in a report on Wednesday, February 18th. Royal Bank Of Canada increased their price objective on shares of Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a research report on Wednesday, November 19th. Barclays reaffirmed an “overweight” rating and set a $118.00 target price on shares of Medtronic in a report on Wednesday, February 18th. Finally, Morgan Stanley increased their price target on shares of Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a report on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Medtronic presently has a consensus rating of “Moderate Buy” and a consensus target price of $110.84.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Received CE mark for its next‑gen GI Genius module and ColonPRO software — expands regulatory clearance and commercial runway in GI imaging, a clear revenue catalyst. Medtronic wins CE mark for next-gen GI Genius module, ColonPRO software
• Positive Sentiment: Recognized at the 2026 Dorian Awards for structured problem‑solving excellence — a reputational boost that supports brand value with hospitals and enterprise customers. 2026 DORIAN AWARDS RECOGNIZE GLOBAL LEADERS IN STRUCTURED PROBLEM-SOLVING EXCELLENCE
• Positive Sentiment: Multiple investor pieces highlight Medtronic’s strong dividend profile and defensive cash flows, reinforcing interest from income-seeking investors and supporting the share price floor. 1 Reason I’d Buy Medtronic Stock and Never Sell
• Neutral Sentiment: BTIG maintained a Hold rating on MDT — not bearish but keeps analyst sentiment from turning strongly positive. BTIG Sticks to Its Hold Rating for Medtronic (MDT)
• Neutral Sentiment: Valuation/returns analysis pieces point to mixed long‑term returns and prompt investors to reassess fair value — supports trading volatility but not a clear directional signal. Is It Time To Reconsider Medtronic (MDT) After Mixed Long Term Share Returns
• Neutral Sentiment: Industry podcast and revenue roundups highlight broader medtech winners from 2025 — useful context for sector positioning but not company‑specific catalysts. Podcast: Which pharma and medtech companies came out on top in 2025 revenues?
• Neutral Sentiment: Coverage of broader trade/tariff uncertainty underscores a macro risk — CEOs want policy clarity, which could affect multinational supply chains and sentiment for global medtech firms like Medtronic. Veteran CEO: President Trump’s chaotic tariff policy is not working

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).